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Rat pial microvascular responses to melatonin during bilateral
common carotid artery occlusion and reperfusion
Introduction
Melatonin, an indoleamine synthesized in the pineal gland
during the dark period in all mammalian species, has
been shown to exert potent antioxidant activity [1, 2].
Both in vitro and in vivo studies indicate that melatonin
protects cells and tissues against oxidative damage
induced by free radical-generating agents [3–5]. Several
studies demonstrated that melatonin scavenges hydroxyl
and peroxyl radicals and is a more potent antioxidant
than vitamin E, mannitol, and glutathione [1, 6–9].
Manev and Uz [10] reported that pinealectomized rats
are vulnerable to kainate-induced excitotoxicity and
photothrombotic brain injury [9]. Moreover, recent stud-
ies have reported beneﬁcial eﬀects exerted by melatonin
against cerebral global and focal ischemia–reperfusion
(RE) injury [11–14].
Melatonin exerts receptor-mediated eﬀects at physiolog-
ical concentrations, whereas the receptor-independent
actions can be achieved by both physiological and phar-
macological concentrations [15]. Two melatonin receptors,
MT1 and MT2, belonging to the G-protein-coupled recep-
tor superfamily, have been cloned in mammals and share
some speciﬁc short amino acid sequences, suggesting that
they represent a speciﬁc subfamily. A third melatonin-
binding site has been puriﬁed and characterized as the
enzyme quinone reductase 2 (MT3); the inhibition of this
enzyme by melatonin may contribute to its anti-oxidative
properties [16, 17].
In vivo experimental studies observed that melatonin
causes constriction of rat cerebral arterioles and facilitates
the cerebral blood ﬂow autoregulation, suggesting that
melatonin may diminish the risk of hypoperfusion-induced
cerebral ischemia [18]. Moreover, melatonin increases the
cerebrovascular dilatory capacity by constriction of the
large cerebral inﬂux arteries. The in vitro melatonin-induced
constriction of large-diameter cerebral arteries is triggered
by G protein-dependent inhibition of Ca2+-activated
large-conductance K+ channels (BKCa) [19, 20].
In contrast, few data have been reported on melatonins
eﬀects on small diameter cerebral arterioles mainly
involved in cerebral blood ﬂow autoregulation. Today,
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the molecular mechanisms underlying the eﬀects of mel-
atonin on pial microcirculation have not been completely
clariﬁed.
The present study investigated the in vivo pial microvas-
cular responses induced by melatonin during brain hypop-
erfusion and RE injury induced by transient bilateral
common carotid artery occlusion (BCCAO) in the rat.
Furthermore, we assessed the diameter changes of pial
arterioles caused by diﬀerent doses of melatonin, and we
evaluated the eﬀect on pial arteriolar diameter by MT1,
MT2, and MT3 melatonin receptor inhibition under
baseline and hypoperfusion conditions.
Materials and methods
Experimental groups
The study was carried out in male Wistar rats weighing
250–300 g (Harlan, Italy) randomly assigned to the
following groups: (i) Sham-operated rats (group SO,
n = 11) subjected to the same procedures as the exper-
imental groups except for the BCCAO; (ii) Control rats
(group C, n = 15) were treated with 1.5-mL vehicle
(physiological saline solution containing 4% ethanol),
intravenously (i.v.) injected, and subjected to 30 min of
BCCAO and 60 min of RE; (iii) The third group
(subgroup Ma, n = 15; subgroup Mb, n = 15; subgroup
Mc, n = 15) was treated with i.v. melatonin, 0.5, 1.0, and
2.0 mg/kg body weight (b.w.), respectively, and infused in
3, 10 min before BCCAO, and at the beginning of RE;
(iv) The fourth group (subgroup LMc1, n = 15 subgroup
LMc2, n = 15) was treated with i.v. luzindole, a speciﬁc
inhibitor of MT2 melatonin receptors and a speciﬁc
inhibitor of MT1 melatonin receptors, at dosage of 2.0
and 4.0 mg/kg b.w., respectively. Luzindole was infused
prior to the highest dose of melatonin and administered
10 min before BCCAO and at the beginning of RE;
(v) The ﬁfth group of rats (PMc, n = 15) was treated with
i.v. prazosin, speciﬁc inhibitor of MT3 melatonin recep-
tors, at dosage of 1.0 mg/kg b.w., infused prior to the
highest dose of melatonin, and administered 10 min before
BCCAO and at the beginning of RE. In groups SO, C,
Ma, Mb, Mc, LMc1, LMc2, and PMc, three of 15 rats
were treated with artiﬁcial cerebrospinal ﬂuid (aCSF)
containing 250.0 mm 2¢-7¢dichloroﬂuorescein-diacetate
(DCFH-DA) during BCCAO and three animals at RE.
(vi) The sixth group of rats (subgroups L1, L2, and P
group, n = 9, respectively) was subjected to i.v. admin-
istration of luzindole (2.0 and 4.0 mg/kg b.w.) or prazosin
(1.0 mg/kg b.w.) 10 min before BCCAO and the beginning
of RE. (vii) Finally, the last group of animals was treated
with melatonin (0.5 mg/kg b.w., 1.0 mg/kg b.w. and
2.0 mg/kg b.w., n = 5 for each dose) or luzindole
(2.0 mg/kg b.w, 4.0 mg/kg b.w., n = 5 for each dose) or
prazosin (1.0 mg/kg b.w., n = 5) without BCCAO and
RE.
In pilot experiments, we examined the eﬀects of luzindole
and prazosin at the diﬀerent doses administered prior to
melatonin treatment (2.0 mg/kg b.w.). Based in the out-
come of these studies, we did not observe signiﬁcant
changes when compared with LMc1, LMc2, and PMc
groups (Table 1).
Table 1. Drug treatment (T): doses, route, and time of administration in the diﬀerent experimental groups
Group H/R plus T Time N Group NO H/R plus T Time N
C Saline solution
1.5 mL i.v.
Prior BCCAO
At Reperfusion
beginning
15 SO Saline solution
1.5 mL i.v.
Twice at 50-min interval 11
Ma Melatonin
0.5 mg/kg b.w. i.v.
Prior BCCAO
At R beginning
15 ma Melatonin
0.5 mg/kg b.w. i.v.
Twice at 50-min interval 5
Mb Melatonin
1.0 mg/kg b.w. i.v.
Prior BCCAO
At R beginning
15 mb Melatonin
1.0 mg/kg b.w. i.v.
Twice at 50-min interval 5
Mc Melatonin
2.0 mg/kg b.w. i.v.
Prior BCCAO
At R beginning
15 mc Melatonin
2.0 mg/kg b.w. i.v.
Twice at 50-min interval 5
LMc1 Luzindole
2.0 mg/kg b.w. i.v.
Melatonin
2.0 mg/kg b.w. i.v.
Prior Melatonin
Prior BCCAO
At R beginning
15 l1 Luzindole
2.0 mg/kg b.w. i.v.
Twice at 50-min interval 5
LMc2 Luzindole
4.0 mg/kg b.w. i.v.
Melatonin
2.0 mg/kg b.w. i.v.
Prior Melatonin
Prior BCCAO
At R beginning
15 l2 Luzindole
4.0 mg/kg b.w. i.v.
Twice at 50-min interval 5
PMc Prazosin
1.0 mg/kg b.w. i.v.
Melatonin
2.0 mg/kg b.w. i.v.
Prior Melatonin
Prior BCCAO
At R beginning
15 p Prazosin
1.0 mg/kg b.w. i.v.
Twice at 50-min interval 5
L1 Luzindole
2.0 mg/kg b.w. i.v.
Prior BCCAO
At R beginning
9
L2 Luzindole
4.0 mg/kg b.w. i.v.
Prior BCCAO
At R beginning
9
P Prazosin
1.0 mg/kg b.w. i.v.
Prior BCCAO
At R beginning
9
H/R, animals subjected to hypoperfusion and reperfusion and NO H/R animals not subjected to hypoperfusion and reperfusion; N, number
of rats utilized; BCCAO, bilateral common carotid artery occlusion.
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Administration of drugs
Melatonin solutions were prepared by dissolving 0.5, 1.0,
and 2.0 mg/kg b.w. in 0.5 mL of saline solution containing
4% ethanol and i.v. infused (3 min) to the rats 10 min
before BCCAO and at the beginning of RE.
Luzindole (2.0 and 4.0 mg/kg b.w.) and prazosin
(1.0 mg/kg b.w.) were dissolved in 0.5 mL of saline
solution, respectively. Each substance was i.v. administered
10 min prior to melatonin (2.0 mg/kg b.w.).
2¢-7¢Dichloroﬂuorescein-diacetate was mixed with aCSF
to obtain a concentration of 250.0 mm. This solution was
superfused over the pial surface for 15 min during ischemia
or at RE.
These drugs were purchased from Sigma Chemical,
St. Louis, MO, USA.
Animal surgical preparation
Anaesthesia was induced with achloralose (50.0 mg/kg
b.w., i.p.) plus urethane (600.0 mg/kg body weight, i.p.)
and maintained with urethane (100.0 mg/kg b.w., i.v. every
hour). Rats were tracheotomized, paralyzed with tubocu-
rarine chloride (1.0 mg/kg h, i.v.), and mechanically venti-
lated with room air and supplemental oxygen. The right
and left common carotid arteries were isolated for succes-
sive clamping. A catheter was placed in the left femoral
artery for arterial blood pressure recording and blood gases
sampling. Another catheter was placed in the right femoral
vein for the ﬂuorescent tracer injection [ﬂuorescein isothi-
ocyanate bound to dextran, molecular weight 70 kDa (FD
70), 50 mg/100 g b.w., i.v. as 5.0% wt/vol solution in 3 min
administered just once at the beginning of experiment after
30 min of the preparation stabilization; rhodamine 6G,
1.0 mg/100 g b.w. in 0.3 mL, as a bolus with supplemental
injection throughout BCCAO and RE (ﬁnal volume
0.3 mL/100 g/h) to label leukocytes for adhesion evalua-
tion] and for drug administration. Blood gas measurements
were carried out on arterial blood samples withdrawn from
arterial catheter at 30-min time period intervals (ABL5;
Radiometer, Copenhagen, Denmark). Throughout all
experiments, mean arterial blood pressure (MABP), heart
rate, respiratory CO2, and blood gases values were recorded
and maintained stable within physiological ranges. Rectal
temperature was monitored and preserved at 37.0 ± 0.5C
with a heating stereotaxic frame where the rats were
secured.
A closed cranial window (4 · 5 mm) was implanted
above the left frontoparietal cortex (posterior 1.5 mm to
bregma; lateral, 3 mm to the midline) to observe the pial
microcirculation [21]. To prevent overheating of the cere-
bral cortex during drilling, cold saline solution was suﬀused
on the skull. The dura mater was gently removed and a
150 lm-thick-quartz microscope cover glass was sealed to
the bone with dental cement. The window inﬂow and
outﬂow were assured by two needles secured in the dental
cement of the window, so that the brain parenchyma was
continuously superfused with aCSF [22, 23]. The rate of
superfusion was 0.5 mL/min controlled by a peristaltic
pump. During superfusion, the intracranial pressure was
maintained at 5 ± 1 mmHg and measured by a pressure
transducer connected to a computer. The composition of
the aCSF was as follows: 119.0 mm NaCl, 2.5 mm KCl,
1.3 mm MgSO4Æ7H2O, 1.0 mm NaH2PO4, 26.2 mm NaH-
CO3, 2.5 mm CaCl2, and 11.0 mm glucose (equilibrated
with 10.0% O2, 6.0% CO2, and 84.0% N2; pH
7.38 ± 0.02). The temperature was maintained at
37.0 ± 0.5C [24].
Cerebral blood ﬂow reduction was produced by place-
ment of two atraumatic microvascular clips for 30 min on
common carotid arteries, previously isolated. After clamp
removing, the pial microcirculation was observed for
60 min (RE period).
The experiments were carried out in the morning from
08.00 am to 02.00 pm, with at least two animals studied per
day, with random distribution for the diﬀerent experimen-
tal groups.
All experiments conformed to the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996) and to institutional rules for the care and handling of
experimental animals. This procedure provides that all
animals were euthanized at the end of the experimental
procedure by pentobarbital overdose intravenously admin-
istered. The protocol was approved by the Federico II
University of Naples Ethical Committee.
Intravital microscopy
Pial vessels were observed using a ﬂuorescence microscope
(Leitz Orthoplan, Wetzlar, Germany) ﬁtted with long-
distance objectives [2.5·, numerical aperture (NA) 0.08;
10·, NA 0.20; 20·, NA 0.25; 32·, NA 0.40], a 10· eyepiece,
and a ﬁlter block (Ploemopak, Leitz). Epi-illumination was
provided by a 100-W mercury lamp using the appropriate
ﬁlters for FITC or rhodamine 6G and a heat ﬁlter (Leitz
KG1). The pial microcirculation was televised with a
DAGE MTI 300RC low-light level digital camera and
recorded by a computer-based frame grabber (Pinnacle DC
10 plus; Avid Technology, MA, USA).
Microvascular measurements were made oﬀ-line using a
computer-assisted imaging software system (MIP Image;
CNR, Institute of Clinical Physiology, Pisa, Italy). The
visualization of pial microcirculation was performed for
1 min every 5 min during substance administration and at
the beginning of RE (20 min). Afterwards, recording was
carried out every 10 min during BCCAO and the remaining
RE (Fig. 1). Because of homogeneous responses during
diﬀerent experiments, we chose to report data collected
under baseline conditions, at the end of BCCAO and the
end of RE.
Microvascular parameter evaluation
Under baseline conditions, the arteriolar network was
mapped by stop-frame images and pial arterioles were
classiﬁed according to a centripetal ordering scheme
(Strahlers method, modiﬁed according to diameter), as
previously described [25]. In each animal, two order 4
arterioles, two order 3, and two order 2 arterioles were
studied during each experiment. We do not report the
results related to order 5 and order 1 arterioles because the
Lapi et al.
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large arterioles were located to the peripheral of the cranial
window while the small arterioles penetrated in the cortex.
Arteriolar diameters were measured with a computer-
assisted method (frame by frame). The results of diameter
measurements were in agreement with those obtained by
shearing method (±0.5 lm). The increase in permeability
was calculated and reported as normalized grey levels
(NGL): NGL = (I – Ir)/Ir, where Ir is the average baseline
grey level at the end of vessel ﬁlling with ﬂuorescence
(average of ﬁve windows located outside the blood vessels
with the same windows being used throughout the exper-
imental procedure), and I is the same parameter at the end
of BCCAO or RE. Grey levels ranging from 0 to 255 were
determined by the MIP Image program in ﬁve regions of
interest (ROI) measuring 50 · 50 lm (10· objective). The
same location of ROI during recordings along the micro-
vascular networks was provided by a computer-assisted
device for XY movement of the microscope table.
Adherent leukocytes (i.e., cells on vessel walls that did
not move over a 30-s observation period) were quantiﬁed in
terms of number/100 lm of venular length (v.l.)/30 s using
higher magniﬁcation (10·, 20·, and 32· microscope objec-
tives). In each experimental group, 45 venules were studied.
Perfused capillary length (PCL) was measured by MIP
image in an area of 150 · 150 lm. In this system, the length
of perfused capillaries is easily established by the automated
process because it is outlined by dextran. [26].
The capillary red blood cell velocity (VRBC) was mea-
sured with a computer-assisted method (frame by frame).
To avoid bias because of single operator measurements, the
quantiﬁcation of all microvascular parameters were made
by two independent blinded operators. Their measure-
ments overlapped in all cases.
Analysis of rhythmic diameter changes
All diameter time series were analyzed by temporal and
frequency domains under basal conditions, during BCCAO
and at RE. Data analysis programs were written using
MATLAB (Mathworks Inc., Natick, MA, USA).
The Lomb–Scargle method was used to estimate the
power spectral density of the diameter time series [27]. This
spectral estimation method has been speciﬁcally developed
to manage unevenly time-spaced data series. Although
interpolation appears to be the easier way to obtain evenly
spaced data from unevenly spaced data, as long gaps are
present, these can produce spectra with spurious bulge of
power at low frequencies. The Lomb–Scargle method
mitigates these biases because it evaluates data only at
times actually measured and it weights data on a per point
instead of a per time interval basis; this explains its better
performance compared to fast Fourier transform in the
unevenly spaced data cases.
Reactive oxygen species quantification
Artiﬁcial cerebrospinal ﬂuid containing 250.0 mm DCFH-
DA at 37.0 ± 0.5C was superfused over the pial surface.
The lipophilic DCFH-DA is a stable nonﬂuorescent probe
with a high cellular permeability. DCFH-DA reacts with
intracellular radicals to be converted to its ﬂuorescent
product (DCF). The remaining extracellular DCFH-DA
was washed out with aCSF. The intensity of DCF
ﬂuorescence is proportional to the intracellular radical
oxygen species (ROS) level.
The ﬂuorescence intensity was determined by the use of
an appropriate ﬁlter (522 nm) and the evaluation of NGL,
with the baseline represented by pial surface just superfused
by DCFH-DA [28].
Physiological parameters recording
Mean arterial blood pressure (Viggo-Spectramed P10E2
transducer, Oxnard, CA, USA, connected to a catheter in
the femoral artery) and heart rate were monitored with a
Gould Windograf recorder (model 13-6615-10S, Gould,
OH, USA). Data were recorded and stored in a computer.
Blood gas measurements were carried out on arterial blood
samples withdrawn from arterial catheter at 30-min time
period intervals (ABL5; Radiometer, Copenhagen,
Denmark). The hematocrit was measured under baseline
conditions, at the end of BCCAO and at RE.
Statistical analysis
All reported values are means ± S.D. Data were tested for
normal distribution with the Kolmogorov–Smirnov (KS)
test. Parametric (Students t tests, ANOVA, and Bonfer-
FITC S/I S/M S/I S/M   
R
BCCAO Reperfusion
Rhodamine 6G 
0 10 20 30 40 50 60 70 80 90 100 110 120 130 140
Time (min) 
Fig. 1. Experimental design of drug administration and measurement times. R, recording points; FITC, ﬂuorescent-dextran (70 kDa) and
rhodamine 6G; S/I, saline solution containing 4% ethanol and/or melatonin receptor inhibitor administration (luzindole, prazosin); S/M,
saline solution containing 4% ethanol and/or melatonin administration; BCCAO, bilateral common carotid artery occlusion. Rhodamine
6G was injected after FITC-dextran as a bolus and then infused during BCCAO and reperfusion.
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roni post hoc test) or nonparametric tests (Wilcoxon,
Mann–Whitney and Kruskal–Wallis tests) were used.
Nonparametric tests were applied to compare diameter
and length data among experimental groups because KS
test indicated non-Gaussian distribution of data.
The statistical analysis was carried out by SPSS 14.0
statistical package. Statistical signiﬁcance was set at
P < 0.05.
Results
Pial arterioles were classiﬁed according to diameter, length,
and branching. Capillaries were assigned order 0 and the
arterioles were assigned order 1–5 according to their
branching. Order 5 showed a mean diameter of
63.0 ± 4.5 lm and mean length of 1172 ± 400 lm,
n = 74; order 4: mean diameter 45.5 ± 4.0 lm and mean
length 980 ± 220 lm, n = 198; order 3: mean diameter
34.5 ± 3.0 lm and mean length 485 ± 105 lm, n = 210;
order 2: mean diameter 25.0 ± 2.5 lm and mean length
370 ± 90 lm, n = 248; ﬁnally, order 1 arterioles had
mean diameter of 15 ± 3 lm and mean length of
135 ± 80 lm, n = 260 [29].
Hypoperfusion aﬀected all pial arterioles causing a
progressive decrease in their diameters. At end of BCCAO
in order 4, 3, and 2 vessels, the reduction was by 20 ± 3%,
18 ± 2%, and 17.5 ± 3.0% of baseline (P < 0.01 versus
SO group), respectively (Fig. 2A). The permeability
increase was pronounced (0.20 ± 0.03 NGL, P < 0.01
versus SO group: 0.04 ± 0.02 NGL) (Fig. 3).
The RE induced arteriolar constriction at the beginning,
then dilation, and at 60 min (RE) again constriction by
19.0 ± 2.8%, 12.5 ± 2.0%, and 11.8 ± 1.2% of baseline
in order 4, 3, and 2 arterioles (P < 0.01 versus SO group),
respectively (Fig. 2B).
The permeability rise was marked on venular side (0.45
± 0.04 NGL, P < 0.01 versus SO group: 0.04 ± 0.02
NGL) as well as adhesion of leukocytes to the venular walls
(8 ± 2/100 lm v.l./30 s; P < 0.01 versus SO group) (Figs 3
and 4). The PCL was signiﬁcantly reduced compared with
SO group (by 39.2 ± 6.0% of baseline), while capillary
VRBC decreased to 0.15 ± 0.02 mm/s (P < 0.01 versus SO
group: 0.22 ± 0.03 mm/s).
The animals treated with DCFH-DA superfusion showed
an increased DCF ﬂuorescence intensity at the end of
BCCAO (0.22 ± 0.02 NGL, P < 0.01 versus baseline:
0.03 ± 0.02 NGL), indicating an increase in ROS forma-
tion. The ﬂuorescence was higher at RE in the remaining
animals (0.30 ± 0.03 NGL, P < 0.01 versus baseline)
showing a further increase in ROS production.
Melatonin, at the lowest dosage (0.5 mg/kg b.w.), caused
a reduction in order 4, 3, and 2 arteriole diameters by 13 ±
2%, 11 ± 2%, and 12.0 ± 2.2% of baseline (P < 0.01
versus C group) and a slight increase in microvascular
permeability (0.15 ± 0.02 NGL, P < 0.01 versus C group)
(Figs 2A and 3).
At RE, order 4 and 3 arteriole diameters were reduced by
4.8 ± 2.5% and 4.0 ± 1.7% of baseline, respectively (P <
0.01 versus C group), while order 2 vessels presented an
increase in frequency of rhythmic diameter changes (0.03 ±
0.01 Hz) compared with baseline (0.02 ± 0.01 Hz)
(Fig. 5A,B). The ﬂuorescence leakage was slightly
prevented (0.25 ± 0.03 NGL, P < 0.01 versus C group)
as well as the leukocyte adhesion (5 ± 2/100 lm v.l./30 s,
P < 0.01 versus C group) (Fig. 3). Capillary perfusion
decreased by 32 ± 4% and VRBC increased compared with
controls (0.26 ± 0.04 mm/s, P < 0.01 versus C group).
In rats treated with DCFH-DA, at the end of BCCAO
and at RE, NGL were 0.14 ± 0.02 and 0.21 ± 0.03,
respectively (P < 0.01 versus C group).
Melatonin, at the intermediate dosage (1.0 mg/kg b.w.),
induced arteriole diameter reduction by 6.3 ± 2.2%,
6.0 ± 2.5%, and 5 ± 2% of baseline in order 4, 3, and 2
arterioles, respectively (P < 0.01 versus C group)
and NGL were 0.11 ± 0.03 (P < 0.01 versus controls)
(Figs 2A and 3) at the end of BCCAO.
At RE, each arteriolar order showed a diﬀerent response.
Order 4 arteriole diameters were increased by 4.2 ± 2.0%
–25
–20
–15
–10
–5
0
5
°*
°*
°*°*
°*°*
°*°*°*°*
°*°*
°*
°*
°
°
°°°
SO C Ma Mb Mc LMc1 LMc2 PMc
D
ia
m
et
er
 a
rt
er
io
la
r c
ha
ng
e 
(%
)
Order 4
Order 3
Order 2
°
°*
–25
–20
–15
–10
–5
0
5
10
15
20
25
°
°
°
°*
°*
°*
°*
°*
°*
°*
°*
°*
°*
°*
°*
°*
°
°
°
D
ia
m
et
er
 a
rt
er
io
la
r c
ha
ng
e 
(%
)
Order 4
Order 3
Order 2
SO C Ma Mb Mc LMc1 LMc2 PMc
(A)
(B)
Fig. 2. Diameter changes of order 4, 3, and 2 arterioles, expressed
as percentage, at the end of bilateral common carotid artery
occlusion (A) and at the end of reperfusion (B) in the experimental
groups: SO, sham-operated group (n = 5); C, control group; Ma,
melatonin 0.5 mg/kg b.w. subgroup (n = 9); Mb, melatonin
1.0 mg/kg b.w. subgroup (n = 9); Mc, melatonin 2.0 mg/kg b.w.
subgroup (n = 9); LMc1, luzindole (2.0 mg/kg b.w.) plus mela-
tonin (2.0 mg/kg b.w.) group (n = 9); LMc2, luzindole (4.0 mg/kg
b.w.) plus melatonin (2.0 mg/kg b.w.) group (n = 9); PMc,
prazosin (1.0 mg/kg b.w.) plus melatonin (2.0 mg/kg b.w.) group
(n = 9). The bar lacking indicates presence of rhythmic diameter
changes. P < 0.01 versus SO group, * P < 0.01 versus C group.
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of baseline (P < 0.01 versus C group) and order 3 vessel
diameters were reduced by 3.8 ± 1.2% of baseline, while
order 2 arterioles showed a signiﬁcant increase in frequency
of rhythmic diameter changes (0.05 ± 0.02 Hz) compared
with baseline (Figs 2B and 5A,C). The microvascular
leakage and leukocyte adhesion were prevented
(0.16 ± 0.03 NGL and 3 ± 1/100 lm v.l./30 s, respec-
tively; P < 0.01 versus C group). The capillary perfusion
was protected, because the decrease was by 27 ± 5% of
baseline (P < 0.01 versus C group) and VRBC increased
(0.30 ± 0.03 mm/s, P < 0.01 compared with controls).
In rats treated with DCFH-DA, at the end of BCCAO
and at RE, NGL were 0.10 ± 0.03, and 0.16 ± 0.03
(P < 0.01 versus controls).
Melatonin at the highest dosage (2.0 mg/kg b.w.) blunted
pial arteriolar diameter decrease at the end of BCCAO:
order 4, 3, and 2 vessels showed a decrease in diameter by
5.5 ± 1.8%, 5.0 ± 2.1%, and 4.6 ± 2.0% of baseline,
respectively (P < 0.01 versus C group) (Fig. 2A). Micro-
vascular permeability was signiﬁcantly reduced compared
with controls (0.04 ± 0.02 NGL, P < 0.01 versus C
group) (Fig. 3).
At RE, the highest dosage caused an increase in diameter
of order 4, 3, and 2 arterioles (by 17.5 ± 2.5%,
12.5 ± 2.0%, and 8.0 ± 1.5% of baseline, respectively,
P < 0.01 versus C group) (Fig. 2B) and prevented ﬂuores-
cent leakage (0.05 ± 0.02 NGL, P < 0.01 versus C group)
(Fig. 3). Leukocyte adhesion decreased (2 ± 1/100 lm v.l./
30 s, P < 0.01 versus C group,) and capillary perfusion
was protected, because the decrease was by 20 ± 4% of
baseline (P < 0.01 versus C group), and VRBC increased
(0.33 ± 0.03 mm/s, P < 0.01 compared with controls).
In rats treated with DCFH-DA, at the end of BCCAO
and at RE, NGL were 0.05 ± 0.02 and 0.06 ± 0.03,
P < 0.01 versus controls, indicating a marked reduction in
ROS production when compared with controls.
Finally, melatonin administration (0.5, 1.0, and 2.0 mg/
Kg b.w.), in rats not subjected to BCCAO and RE, did not
aﬀect microvascular parameters when compared with those
observed in SO group.
Luzindole, at the lower dosage (2.0 mg/kg b.w.) prior to
melatonin (2.0 mg/kg b.w.), partially reduced the eﬀects of
melatonin because the diameter of order 4, 3, and 2
arterioles diminished by 10.0 ± 1.5%, 9.0 ± 2.0%, and
9.3 ± 1.4% of baseline, respectively (P < 0.01 versus C
group), at the end of BCCAO (Fig. 2A). The permeability
increase did not signiﬁcantly change compared with SO
group (Fig. 3).
At RE, pial arterioles showed a slight increase in
diameter (by 14.2 ± 2.0%, 10.0 ± 1.5%, and 6.5 ±
1.0% of baseline, in order 4, 3, and 2 respectively
(P < 0.01 versus controls) (Fig. 2B). The permeability
increase and leukocyte adhesion were prevented as
observed in rats treated with the highest dosage of
melatonin (Fig. 3). PCL was slightly reduced (by 23 ±
5% of baseline, P < 0.01 versus C group; P = NS versus
Mc subgroup) while VRBC increased (0.25 ± 0.03 mm/s,
P < 0.01 versus C group; P = NS versus Mc subgroup).
Luzindole, at the higher dose (4 mg/kg b.w.) prior to
melatonin (2 mg/kg b.w.), abolished melatonin-induced
eﬀects in order 4, 3, and 2 arterioles: arteriolar diameter
decreased by 17.0 ± 3.2%, 14.1 ± 3.0%, and
15.2 ± 3.5% of baseline, respectively, P = NS versus
controls at the end of BCCAO. Microvascular leakage
was prevented as observed in Mc subgroup (Figs 2A and 3).
At RE, luzindole blunted melatonin-induced vasodila-
tion. Pial arterioles constricted by 18.0 ± 3.5%,
13.0 ± 1.8%, and 12.0 ± 1.5% of baseline in order 4, 3,
and 2, respectively (P = NS versus controls) (Fig. 2B).
Leakage and leukocyte adhesion were prevented
(0.05 ± 0.03 NGL, 3.0 ± 1.0/100 lm v.l./30 s; P < 0.01
versus controls) (Fig. 3). PCL decreased by 25 ± 5% of
baseline and VRBC was 0.27 ± 0.03 mm/s, P < 0.01 versus
controls.
In DCFH-DA-treated animals, NGL were not signiﬁ-
cantly diﬀerent when compared with Mc subgroup inde-
pendently of luzindole dosage utilized.
Luzindole (2.0 and 4.0 mg/kg b.w.), administered prior
to BCCAO and at the beginning of RE, did not modify the
microvascular responses observed in control rats. Luzin-
dole (2.0 and 4.0 mg/kg b.w.) treatment in animals not
subjected to BCCAO and RE did not aﬀect microvascular
parameters when compared with those observed in SO
group. The luzindole dosages were chosen according to
previous data [29].
Prazosin (1.0 mg/kg b.w.) prior to melatonin (2.0 mg/kg
b.w.) did not modify the melatonin eﬀects because at the
end of BCCAO, order 4, 3, and 2 vessels showed a slight
decrease in diameter by 6.0 ± 1.5%, 5.1 ± 2.0%, and
4.5 ± 1.5% of baseline, respectively (P < 0.01 versus C
group) (Fig. 2A). Microvascular permeability did not
signiﬁcantly change compared with baseline (Fig. 3). At
RE, prazosin plus melatonin caused dilation of order 4, 3,
and 2 arterioles (by 16.8 ± 1.5%, 11.5 ± 1.4%, and
7 ± 2% of baseline, respectively, P < 0.01 versus C
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Fig. 3. Permeability increase, expressed as normalized grey levels,
after bilateral common carotid artery occlusion (black) and at
reperfusion (grey) in the experimental groups: SO, sham-operated
group (n = 5); C, control group (n = 9); Ma, melatonin 0.5 mg/
kg b.w. subgroup (n = 9); Mb, melatonin 1.0 mg/kg b.w. sub-
group (n = 9); Mc, melatonin 2.0 mg/kg b.w. subgroup (n = 9);
LMc1, luzindole (2.0 mg/kg b.w.) plus melatonin (2.0 mg/kg b.w.)
group (n = 9); LMc2, luzindole (4.0 mg/kg b.w.) plus melatonin
(2.0 mg/kg b.w.) group (n = 9); PMc, prazosin (1.0 mg/kg b.w.)
plus melatonin (2.0 mg/Kg b.w.) group(n = 9). P < 0.01 versus
SO group, * P < 0.01 versus C group.
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group) (Fig. 2B). Moreover, microvascular permeability
and leukocyte adhesion were prevented as observed in Mc
subgroup (Fig. 3). PCL and VRBC did not show signiﬁcant
changes compared with Mc subgroup.
Moreover, in DCFH-DA-treated animals, NGL did not
signiﬁcantly change when compared with Mc subgroup.
Prazosin (1.0 mg/kg b.w.), administered prior to BCCAO
and at the beginning of RE, did not signiﬁcantly modify the
microvascular responses, such as those observed in control
rats. Prazosin treatment (1.0 mg/kg b.w) of animals not
subjected toBCCAOandREdidnot inﬂuencemicrovascular
parameterswhen comparedwith those observed inSOgroup.
Prazosin dosage was chosen according to previous data [30].
Finally, the physiological parameters, such as hematocrit,
MABP, heart rate, pH, PCO2, and PO2, did not signiﬁcantly
change in the diﬀerent experimental groups up to RE.
Discussion
Cerebral hypoperfusion triggered by bilateral occlusion of
common carotid arteries resulted in arteriolar diameter
reduction and permeability increase. Reperfusion was
characterized by marked arteriolar constriction, pro-
nounced microvascular permeability and adhesion of
leukocytes, and reduction in capillary perfusion and
capillary red blood cell velocity.
Melatonin administered prior to bilateral occlusion of
common carotid arteries and at the beginning of RE dose
dependently prevented microvascular damage. During
BCCAO, melatonin dose dependently prevented arteriolar
diameter decrease and leakage. During RE, the lower
dosages of melatonin modulated the pial arteriolar tone
decreasing the constriction of large arterioles (order 4 and
3), while increasing rhythmic diameter changes in small
arterioles (order 2). This oscillation in rat pial arteriolar
diameter, deﬁned as vasomotion, has been studied during
cortical activation indicating that this phenomenon plays
an important role in the regulation of the coupling between
neuronal activity and hemodynamic response [31]. Previous
studies carried out in diﬀerent experimental models have
shown that rhythmic changes in diameter are able to
modulate distribution of blood ﬂow in the terminal
(C) Mc group
____100 μm
(A) C group
(E) LMc2 group (F) LMc2 group 
(D) Mc group
(B) C group
Fig. 4. Computer-assisted image of a pial
microvascular network in control rat
under baseline conditions (A) and at the
end of reperfusion (B); in rat treated with
melatonin 2.0 mg/kg b.w. (C, D) and in
rat treated with melatonin 2.0 mg/kg b.w.
plus luzindole 4.0 mg/kg b.w. (E, F), at
the same time points as in control. The
increase in permeability is apparent by the
marked changes in the colour of intersti-
tium (from black to white). Melatonin or
melatonin plus luzindole prevented the
increase in permeability because the
interstitium did not signiﬁcantly change in
colour (black). Scale bar = ____100 lm.
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arteriolar branchings [32]. Our data indicate that low-dose
melatonin increased the arteriolar oscillation frequency
during RE, likely improving blood ﬂow distribution in
microvascular networks and consequently cerebral tissue
oxygenation.
The highest dose of melatonin caused dilation of all
arteriolar orders. These results are in agreement with the
data reported by Re´grigny and coworkers [19], who
demonstrated that melatonins topically application (at
low dosage) induces vasoconstriction of pial large arteries
(mean diameter >60 ± 4 lm) while small pial arterioles
dilate. Furthermore, our data indicate that melatonin dose
dependently prevented microvascular permeability and
leukocyte adhesion, and preserved capillary perfusion and
capillary red blood cell velocity.
Luzindole administration prior to melatonin caused
diﬀerent arteriolar responses at the diﬀerent dosages.
Luzindole at the lower dosage caused partial inhibition
of melatonin-induced dilation, while the higher dosage
completely abolished the melatonin-triggered vasodilation
causing pronounced arteriolar diameter reduction as
observed in control animals. Luzindole did not aﬀect
the protective eﬀects of melatonin on BCCAO and
RE-induced injuries, such as leakage and leukocyte adhe-
sion. Previous in vitro study carried out in rats indicate
that lower dosage of luzindole inhibits MT2 melatonin
receptors, while higher dosage inhibits MT1 and MT2
melatonin receptors [33].
The data of the present study suggest that melatonin
modulates the pial arteriole tone during hypoperfusion and
RE. Melatonin activates MT1 and MT2 receptors; it is
possible to suggest that the lower dosage of melatonin
activated MT2 receptors, while the higher dosage of
melatonin was able to stimulate also MT1 receptors.
However, the stimulation of MT2 melatonin receptors
induced rhythmic diameter changes in smaller arterioles,
contributing to the microvascular blood ﬂow regulation
during ischemia–RE. However, melatonin exhibited further
eﬀects preventing microvascular injuries. This protection
was independent of MT1 and MT2 melatonin receptor
activation. These eﬀects are probably due to antioxidant
activity as indicated by our data in DCFH-DA-treated
animals.
MT3 melatonin receptor inhibition by prazosin did not
alter melatonin-induced protective eﬀects during hypoper-
fusion and RE. MT3 melatonin receptor is a quinone
reductase two whose intracellular signaling pathway has
not been fully clariﬁed. It was suggested that MT3
melatonin receptors may contribute to melatonin antioxi-
dant properties [34]. Our data conﬁrm melatonin scavenger
activity, but prazosin administration did not interfere with
melatonin antioxidant eﬀects. These results are supported
by reports documenting the ability to detoxify free radicals
and related oxygen derivatives by melatonin is likely due to
a receptor-independent pathway [35].
In conclusion, it is reasonable to suggest that melatonins
protective mechanisms against brain ischemia–RE injury
may be because of diﬀerent actions. Melatonin modulates
the arteriolar tone promoting an eﬃcient redistribution of
microvascular blood ﬂow; this activity is mediated by MT1
and MT2 melatonin receptors. Moreover, melatonin has a
powerful scavenger activity against the oxygen-derived free
radicals with slight or no involvement of MT3 melatonin
receptors. All these properties contribute to melatonins
eﬀects that appear to ameliorate brain ischemia and RE
damages.
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Fig. 5. Rhythmic diameter changes in order 2 arteriole of a rat
under baseline conditions (down) and after treatment with mela-
tonin (1 mg/kg b.w., Mb subgroup) (upper) (A). Corresponding
power spectra under baseline conditions (B) and after treatment
with melatonin (1 mg/kg b.w., Mb subgroup) (C). PSD: power
spectral density (lm2/Hz).
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